Table 1 Demographic characteristics of the included studies
First author (Year) | Country | Study population | Gender | Mean age (year) | Sample size | Loss to-follow up | Compliance | Study duration | Findings |
|---|---|---|---|---|---|---|---|---|---|
Wong et al. (2020) | Australia | post menopause women | F | Placebo: 65.8 ± 1.3 Resv: 64.3 ± 1.3 | Placebo: 65 Resv: 63 | Placebo: 11% Resv: 14% | Placebo: 95% Resv: 94% | 12 months | 12 months supplementation with resveratrol increases BMD in lumbar spine and neck of femur in postmenopausal women. |
Ornstrup et al. (2014) | Denmark | obese men with metabolic syndrome | M | Placebo: 48.2 ± 6.4 Low dose: 48.9 ± 6.5 High dose: 50.9 ± 5.9 | Placebo: 24 Low dose: 21 High dose: 21 | Placebo: 8% Low dose: 9% High dose: 16% | Placebo: 97% Low dose: 93% High dose: 96% | 16 weeks | High dose resveratrol supplementation increases serum BAP level and vBMD in lumber spine in a dose-dependent manner in obese men. |
Bo et al. (2018) | Italy | type 2 diabetes patients | F/M | Placebo: 65.4 ± 8.8 Low dose: 64.9 ± 8.6 High dose: 65.0 ± 7.6 | Placebo: 58 Low dose: 59 High dose: 62 | Placebo: 6% Low dose: 9% High dose: 5% | > 95% overall | 6 months | 6 months supplementation of 500 mg resveratrol increases whole body BMD and BMC and serum ALP in type 2 diabetes. |
Poulsen et al. (2014) | Denmark | obese nondiabetic men | M | Placebo: 31.9 ± 2.9 Resv: 44.7 ± 3.5 | Placebo: 12 Resv: 12 | Placebo: 0% Resv: 1% | Placebo: 89.2% Resv: 88.9% | 4 weeks | Short term supplementation of resveratrol increases plasma level of BAP in obese non-diabetic men but not other bone markers. |
Heebøll et al. (2016) | Denmark | non-alcoholic fatty liver disease | F/M | *Placebo: 43.5 (21–69) Resv: 43.2 (22–67) | Placebo: 13 Resv: 13 | Placebo: 0% Resv: 1% | Placebo: 97% Resv: 81% | 6 months | 6 months supplementation of resveratrol did not significantly increase serum ALP compared with placebo. |
Anton et al. (2014) | USA | healthy elderly | F/M | Placebo: 73.3 ± 2.06 Low dose: 73.17 ± 2.08 High dose: 73.60 ± 2.53 | Placebo: 10 Low dose: 12 High dose: 10 | Placebo: 17% Low dose: 14% High dose: 23% | Placebo: 93% Low dose: 93% High dose: 93% | 3 months | 12 weeks supplementation of high-dose resveratrol significantly increased serum ALP compared with placebo but not Ca. |
Movahed et al. (2013) | Iran | type 2 diabetic patients | F/M | Placebo: 51.81 ± 6.99 Resv: 52.45 ± 6.18 | Placebo: 31 Resv: 33 | Placebo: 0% Resv: 3% | unclear | 6 weeks | 6 weeks supplementation of resveratrol did not significantly increase serum ALP compared with placebo. |
Asghari et al. (2018) | Iran | non-alcoholic fatty liver disease | F/M | *Placebo: 38.50 (30, 48) Resv: 40.00 (22, 58) | Placebo: 26 Resv: 25 | Placebo: 13% Resv: 17% | over 90% overall | 12 weeks | 12 weeks supplementation of resveratrol did not significantly increase serum ALP compared with placebo. |
Tomé-Carneiro et al. (2013) | Spain | type 2 diabetes and hypertensive patients with coronary artery disease | M | GE placebo: 60 ± 10 GE with resv: 63 ± 12 | GE placebo: 13 GE with resv: 13 | GE placebo: 0% GE with resv: 0% | > 95% | 12 months | 12 months supplementation with resveratrol significantly reduced serum ALP. |
van der Made et al. (2015) | Italy | overweight and obese subjects | F/M | Overall: 60 ± 7 | Placebo: 22 Resv: 23 | GE placebo: 12% GE with resv: 8% | 99% | 4 weeks | 4 weeks supplementation with resveratrol significantly increased serum ALP compared with placebo. |